trending Market Intelligence /marketintelligence/en/news-insights/trending/qGF6hpamslNkeglE4-0jAQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sumitomo fails to reach agreement to acquire Cynata Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sumitomo fails to reach agreement to acquire Cynata Therapeutics

Sumitomo Dainippon Pharma Co. Ltd. failed to reach an agreement on terms to acquire stem cell technology company Cynata Therapeutics Ltd.

The parties have withdrawn from the acquisition discussions after failing to arrive at a deal.

The Osaka, Japan-based drugmaker previously offered to acquire Australia's Cynata for A$2 per share in cash under a scheme of agreement.

The offer, made in July, valued the stem cell and regenerative medicines company at about A$203.8 million.

Sumitomo manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics and other products.

Cynata, which offers a mesenchymal stem cell technology, is developing its lead product candidate CYP-001 as a treatment for graft versus host disease.